Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Dissolution testing process

A spectrum in a specified ranalogue signals from eadi photodiode are digitised and transferred to a computer, where they e corrected for dark current response and transformed to absorbance. A number of digital techniques are available to increase sensitivity and to extend the use of rapid-scanning detectors to multicomponent analysis, reaction kinetics, tablet dissolution tests, process control, and detection in HPLC (A. F. Fell et al, Chrom-atographia, 1982, 16, 69-78). [Pg.226]

The BCS has been developed primarily for regulatory applications, although its use has been extended beyond this area (as discussed in more detail below). The aim of the BCS in a regulatory context is to provide a basis for replacing certain bioequivalence studies by equally or more accurate in vitro dissolution tests. This could reduce costs and time in the development process as well as reducing unnecessary drug exposure in healthy volunteers, which is normally the study population in bioequivalence studies. [Pg.514]

The BCS could be used as a framework for predictions when IVIVC could be expected for solid IR products, as summarized in Table 21.5. It is important to realize that the in vitro dissolution test only models the release and dissolution of the active drug substance from the formulation, and it is only when these processes are rate-limiting in the absorption process that IVIVC can be expected. In... [Pg.520]

The absorption of class III drugs is limited by their permeability over the intestinal wall. Thus, as this process is not at all modeled by the classical in vitro dissolution test, no IVIVC should be expected. When drug dissolution becomes slower than gastric emptying, a reduction in the extent of bioavailability will be found in slower dissolution rates as the time when the drug is available for permeation over the gut wall in the small intestine will then be reduced. Thus, the same type of relationship can be expected between bioavailability and in vitro dissolution, as shown in Fig. 21.12 for a class I drug. [Pg.523]

One approach to the study of solubility is to evaluate the time dependence of the solubilization process, such as is conducted in the dissolution testing of dosage forms [70], In this work, the amount of drug substance that becomes dissolved per unit time under standard conditions is followed. Within the accepted model for pharmaceutical dissolution, the rate-limiting step is the transport of solute away from the interfacial layer at the dissolving solid into the bulk solution. To measure the intrinsic dissolution rate of a drug, the compound is normally compressed into a special die to a condition of zero porosity. The system is immersed into the solvent reservoir, and the concentration monitored as a function of time. Use of this procedure yields a dissolution rate parameter that is intrinsic to the compound under study and that is considered an important parameter in the preformulation process. A critical evaluation of the intrinsic dissolution methodology and interpretation is available [71]. [Pg.26]

Dissolution testing of pharmaceutical dosage forms, one of the most frequent tasks to be performed in a pharmaceutical laboratory, is another laborious and time-consuming process that generates a... [Pg.270]

Most manufacturers of dissolution testing devices offer semi-automated systems that can perform sampling, filtration, and UV reading or data collection. These systems automate only a single test at a time. Fully automated systems typically automate entire processes including media preparation, media dispensing, tablet or capsule drop, sample removal, filtration, sample collection or analysis (via direct connection to spectrophotometers or HPLCs), and wash cycles. A fully automated system allows automatic performance of a series of tests to fully utilize unused night and weekend instrument availability. [Pg.271]

The European Pharmacopoeia (Ph. Eur.) has also adopted some of the apparatus designs (12) described in the USP, with some minor modifications in the specifications. Small but persistent differences between the two have their origin in the fact that the American metal processing industry, unlike the European, uses the imperial rather than the metric system. In the European Pharmacopeia, official dissolution testing apparatus for special dosage forms (medicated chewing gum, transdermal patches) have also been incorporated (Table 2 provides an overview of apparatus in Ph. Eur.). [Pg.16]

When performing dissolution testing, there are many ways that the test may generate erroneous results. The testing equipment and its environment, handling of the sample, formulation, in situ reactions, automation and analytical techniques can all be the cause of errors and variability. The physical dissolution of the dosage form should be unencumbered at all times. Certain aspects of the equipment calibration process may show these errors as well as close visual observation of the test. The essentials of the test are accuracy of results and robustness of the method. Aberrant and unexpected results do occur, however, and the analyst should be well trained to examine all aspects of the dissolution test and observe the equipment in operation. [Pg.58]

Over the last quarter century the dissolution test has emerged as a most powerful and valuable tool to guide formulation development, monitor the manufacturing process, assess product quality, and in some cases to predict in vivo performance of solid oral dosage forms. Under certain conditions, the dissolution test can be used as a surrogate measure for bioequivalence (BE) and to provide biowaivers, assuring BE of the product. Dissolution test has turned out to be a... [Pg.81]

In general, it is preferable to choose excipients and processes for IR dosage forms that do not result in a formulation that requires a particular pH to function well. In the general population, the pH in the stomach is quite variable (see the subsection Choice of Dissolution Test Conditions for Quality Control ) and there is no guarantee that the dosage form will be exposed to acid, so dosage forms that require acid to facilitate release are unlikely to perform robustly in the clinical practice setting. [Pg.203]

To simulate conditions lower in the small intestine, media are buffered at higher pH values and contain progressively lower concentrations of bile salts (see also the section Dissolution Test Design for MR Products ). These compositions reflect the active re-absorption of bile salts from the ileum, a process which is about 95% efficient, and the trend to higher pH as one moves further away from the pylorus. [Pg.207]


See other pages where Dissolution testing process is mentioned: [Pg.363]    [Pg.364]    [Pg.810]    [Pg.205]    [Pg.208]    [Pg.209]    [Pg.517]    [Pg.526]    [Pg.355]    [Pg.259]    [Pg.262]    [Pg.271]    [Pg.5]    [Pg.15]    [Pg.29]    [Pg.31]    [Pg.33]    [Pg.34]    [Pg.76]    [Pg.94]    [Pg.128]    [Pg.182]    [Pg.195]    [Pg.204]    [Pg.308]    [Pg.320]    [Pg.321]    [Pg.345]    [Pg.353]    [Pg.355]    [Pg.365]    [Pg.393]    [Pg.396]    [Pg.432]    [Pg.432]    [Pg.433]    [Pg.435]   
See also in sourсe #XX -- [ Pg.396 ]




SEARCH



Dissolution process

Dissolution testing

Process Testing

Processability testing

Tests process

© 2024 chempedia.info